AVI BioPharma to Present at the BioCentury NewsMakers in the Biotech Industry Conference
October 19 2010 - 8:30AM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, announced today that the company is scheduled to
present at the 17th Annual NewsMakers in the Biotech Industry
Conference in New York City on Friday, October 22 at 9:30 a.m.
Eastern Time. J. David Boyle II, AVI's Interim President and Chief
Executive Officer, and Chief Financial Officer, will provide a
company overview.
The conference presentation will be webcast live under the
events section of AVI's website at www.avibio.com, and will be
archived there following the presentation. Please connect to AVI's
website several minutes prior to the start of the broadcast to
ensure adequate time for any software download that may be
necessary.
About BioCentury
NewsMakers In The Biotech Industry
Conference
BioCentury is recognized as the essential provider of
independent, informed business intelligence that regularly affects
decisions made by bio-industry leaders and investors throughout the
world. The 17th Annual NewsMakers in the Biotech Industry
Conference, presented by BioCentury and Thomas Reuters, anticipates
the news by featuring companies with major product and earnings
events that promise to be key to the next upswing. The objective of
NewsMakers is to stimulate interest in a hand-picked group of
public biotech companies with corporate and regulatory milestones
into 2011 and beyond. NewsMakers is recognized as the industry's
key venue for companies to take their story to Wall Street each
Fall. NewsMakers is an opportunity -- in a single day -- for the
investment and pharma business development communities to assess
the prospects for biotech stocks and to compare notes with key
members of the institutional investment and analyst communities and
pharma business development executives.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. Applying pioneering
technologies developed and optimized by AVI, we are able to target
a broad range of diseases and disorders through distinct RNA-based
mechanisms of action. Unlike other RNA-based approaches, our
technologies can be used to directly target both messenger RNA
(mRNA) and precursor messenger RNA (pre-mRNA) to either
down-regulate (inhibit) or up-regulate (promote) the expression of
targeted genes or proteins. By leveraging our highly differentiated
RNA antisense-based technology platform, we have built a pipeline
of potentially transformative therapeutic agents, including a
clinical stage Duchenne muscular dystrophy candidate and
anti-infective candidates for influenza and hemorrhagic fever
viruses. For more information, visit www.avibio.com.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024